AI-Powered Drug Discovery

Dis-Solved is an independent AI-powered platform dedicated to making advanced in silico drug discovery accessible, affordable, and targeted—especially for central nervous system (CNS) therapeutics and safer stimulant design.

Founded and built single-handedly by Nabil Yasini, Dis-Solved started as a personal project on a modest laptop: developing high-performance, interpretable machine learning models that outperform many state-of-the-art benchmarks in key ADMET predictions. What began as a breakthrough blood-brain barrier permeability (BBBP) predictor (achieving 0.92 internal AUC and 0.96 on external validation, with explicit stereoisomer training) has evolved into a modular toolkit tailored for early-stage screening of ADHD and neuropsychiatric drug candidates.

By leveraging clever data augmentation and modern graph neural networks, we've created tools that are not only accurate and explainable but also beginner-friendly and priced for real-world use—starting from free tiers up to affordable subscriptions.

At Dis-Solved, we believe cutting-edge AI shouldn't be locked behind enterprise paywalls or massive teams. We're here to empower academics, small biotechs, indie researchers, and drug hunters to screen smarter, fail faster, and advance safer CNS therapies.

Whether you're a student exploring computational chemistry or a startup optimizing leads, Dis-Solved is your practical partner in dissolving the toughest challenges in drug discovery.